Michaela Dinan, PhD

• Cary Gross
• Henry S. Park
• Jennifer Ellen Miller
• Joseph Ross
• Michael S. Leapman
• Rong Wang
• Sangchoon Jeon
• Timothy Robinson
• Xiaomei Ma

Breast Neoplasms; Carcinoma, Renal Cell; Chronic Disease; Colonic Neoplasms; Costs and Cost Analysis; Epidemiology; Urologic Neoplasms; Risk Assessment; Cancer Survivors

Aging; Cancer; Chronic Diseases; Health Policy; Women's Health; Health Equity, Disparities, Social Determinants and Justice; Pharmacoepidemiology

• Clinician Perspectives on Managing Chronic Pain After Curative-Intent Cancer Treatment.Check D, Jones K, Fish L, Dinan M, Dunbar T, Farley S, Ma J, Merlin J, O'Regan A, Oeffinger K. Clinician Perspectives on Managing Chronic Pain After Curative-Intent Cancer Treatment. JCO Oncology Practice 2023, op2200410. PMID: 36595729, DOI: 10.1200/op.22.00410.
• Genetic testing in privately insured women with surgically treated breast cancerDinan M, Pitafi S, Greenup R, Long J, Gross C. Genetic testing in privately insured women with surgically treated breast cancer Breast Cancer Research And Treatment 2022, 198: 177-181. PMID: 36542252, DOI: 10.1007/s10549-022-06829-4.
• End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy.Dzimitrowicz H, Wilson L, Jackson B, Spees L, Baggett C, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M, Wheeler S. End-of-Life Care for Patients With Metastatic Renal Cell Carcinoma in the Era of Oral Anticancer Therapy. JCO Oncology Practice 2022, op2200401. PMID: 36413741, DOI: 10.1200/op.22.00401.
• Concurrent prescribing of opioids with other sedating medications after cancer diagnosis: a population-level analysisCheck D, Baggett C, Kim K, Merlin J, Oeffinger K, Winn A, Roberts M, Robinson T, Dinan M. Concurrent prescribing of opioids with other sedating medications after cancer diagnosis: a population-level analysis Supportive Care In Cancer 2022, 30: 9781-9791. PMID: 36396793, DOI: 10.1007/s00520-022-07439-y.
• Health Services ResearchDinan M, Check D. Health Services Research 2022, 1-13. DOI: 10.1002/9781119000822.hfcm051.pub2.
• T066: Treatment and sex-specific exposure-based risk-stratification for care of survivors of childhood Hodgkin Lymphoma: A report from the Childhood Cancer Survivor StudyDinan M, Stratton K, Leisenring W, Yasui Y, Chow E, Tonorezos E, Moskowitz C, Yeh J, Noyd D, Armstrong G, Oeffinger K. T066: Treatment and sex-specific exposure-based risk-stratification for care of survivors of childhood Hodgkin Lymphoma: A report from the Childhood Cancer Survivor Study HemaSphere 2022, 6: 31. PMCID: PMC9642057, DOI: 10.1097/01.hs9.0000890832.67877.a2.
• Treatment patterns and health care resource use of patients with metastatic breast cancer with HER2-low expression: A cancer registry-linked insurance claims study.Check D, Jackson B, Spees L, Dinan M, Kwong J, Mehta S, Wheeler S, Wilson L, Faherty E, Reeder-Hayes K, Lam C. Treatment patterns and health care resource use of patients with metastatic breast cancer with HER2-low expression: A cancer registry-linked insurance claims study. Journal Of Clinical Oncology 2022, 40: 399-399. DOI: 10.1200/jco.2022.40.28_suppl.399.
• Racial and Ethnic Variation in COVID-19 Vaccination Uptake Among Medicare Beneficiaries with Cancer HistoryPoghosyan H, Dinan MA, Tamamyan G, Nelson L, Jeon S. Racial and Ethnic Variation in COVID-19 Vaccination Uptake Among Medicare Beneficiaries with Cancer History Journal Of Racial And Ethnic Health Disparities 2022, 1-9. PMID: 36149576, PMCID: PMC9510246, DOI: 10.1007/s40615-022-01415-2.
• Oral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC)Dinan MA, Wilson LE, Greiner MA, Spees LP, Pritchard JE, Zhang T, Kaye D, George D, Scales CD, Baggett CD, Gross CP, Leapman MS, Wheeler SB. Oral Anticancer Agent (OAA) Adherence and Survival in Elderly Patients With Metastatic Renal Cell Carcinoma (mRCC) Urology 2022, 168: 129-136. PMID: 35878815, PMCID: PMC9588695, DOI: 10.1016/j.urology.2022.07.012.
• Treatment exposure-based risk-stratification for care of survivors of childhood cancer: A report from the Childhood Cancer Survivor Study.Dinan M, Stratton K, Leisenring W, Yasui Y, Chow E, Moskowitz C, Yeh J, Noyd D, Armstrong G, Oeffinger K. Treatment exposure-based risk-stratification for care of survivors of childhood cancer: A report from the Childhood Cancer Survivor Study. Journal Of Clinical Oncology 2022, 40: 10056-10056. DOI: 10.1200/jco.2022.40.16_suppl.10056.
• Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinomaPritchard JE, Wilson LE, Miller SM, Greiner MA, Cohen HJ, Kaye DR, Zhang T, Dinan MA. Association between cognitive impairment and oral anticancer agent use in older patients with metastatic renal cell carcinoma Journal Of The American Geriatrics Society 2022, 70: 2330-2343. PMID: 35499667, PMCID: PMC9378524, DOI: 10.1111/jgs.17826.
• Mediators of Racial Disparity in the Use of Prostate Magnetic Resonance Imaging Among Patients With Prostate CancerLeapman MS, Dinan M, Pasha S, Long J, Washington SL, Ma X, Gross CP. Mediators of Racial Disparity in the Use of Prostate Magnetic Resonance Imaging Among Patients With Prostate Cancer JAMA Oncology 2022, 8: 687-696. PMID: 35238879, PMCID: PMC8895315, DOI: 10.1001/jamaoncol.2021.8116.
• Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents.Spees LP, Dinan MA, Jackson BE, Baggett CD, Wilson LE, Greiner MA, Kaye DR, Zhang T, George DJ, Scales CD, Pritchard JE, Leapman M, Gross CP, Wheeler SB. Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents. Clinical Genitourinary Cancer 2022, 20: e396-e405. PMID: 35595633, PMCID: PMC9529768, DOI: 10.1016/j.clgc.2022.04.010.
• Factors associated with the quality of end-of-life care for patients with metastatic renal cell carcinoma.Dzimitrowicz H, Wilson L, Jackson B, Spees L, Baggett C, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M, Wheeler S. Factors associated with the quality of end-of-life care for patients with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2022, 40: 300-300. DOI: 10.1200/jco.2022.40.6_suppl.300.
• Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinomaKaye DR, Wilson LE, Greiner MA, Spees LP, Pritchard JE, Zhang T, Pollack CE, George D, Scales CD, Baggett CD, Gross CP, Leapman MS, Wheeler SB, Dinan MA. Patient, provider, and hospital factors associated with oral anti-neoplastic agent initiation and adherence in older patients with metastatic renal cell carcinoma Journal Of Geriatric Oncology 2022, 13: 614-623. PMID: 35125336, PMCID: PMC9232903, DOI: 10.1016/j.jgo.2022.01.008.
• Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinomaMiller SM, Wilson LE, Greiner MA, Pritchard JE, Zhang T, Kaye DR, Cohen HJ, Becher RD, Maerz LL, Dinan MA. Evaluation of mild cognitive impairment and dementia in patients with metastatic renal cell carcinoma Journal Of Geriatric Oncology 2022, 13: 635-643. PMID: 34996724, PMCID: PMC9232862, DOI: 10.1016/j.jgo.2021.12.012.
• Risk factors for dementia onset in older adults with metastatic renal cell carcinomaMiller S, Wilson L, Greiner M, Pritchard J, Zhang T, Kaye D, Cohen H, Dinan M. Risk factors for dementia onset in older adults with metastatic renal cell carcinoma Innovation In Aging 2021, 5: 697-697. PMCID: PMC8969788, DOI: 10.1093/geroni/igab046.2613.
• Low-touch, team-based care for co-morbidity management in cancer patients: the ONE TEAM randomized controlled trialZullig LL, Shahsahebi M, Neely B, Hyslop T, Avecilla RAV, Griffin BM, Clayton-Stiglbauer K, Coles T, Owen L, Reeve BB, Shah K, Shelby RA, Sutton L, Dinan MA, Zafar SY, Shah NP, Dent S, Oeffinger KC. Low-touch, team-based care for co-morbidity management in cancer patients: the ONE TEAM randomized controlled trial BMC Primary Care 2021, 22: 234. PMID: 34794388, PMCID: PMC8600877, DOI: 10.1186/s12875-021-01569-8.
• Opioid Prescribing and Use Among Cancer Survivors: A Mapping Review of Observational and Intervention StudiesCheck DK, Avecilla R, Mills C, Dinan MA, Kamal AH, Murphy B, Rezk S, Winn A, Oeffinger K. Opioid Prescribing and Use Among Cancer Survivors: A Mapping Review of Observational and Intervention Studies Journal Of Pain And Symptom Management 2021, 63: e397-e417. PMID: 34748896, DOI: 10.1016/j.jpainsymman.2021.10.015.
• Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer ManagementLeapman MS, Wang R, Park HS, Yu JB, Sprenkle PC, Dinan MA, Ma X, Gross CP. Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association With Prostate Cancer Management JAMA Network Open 2021, 4: e2128646. PMID: 34623406, PMCID: PMC8501394, DOI: 10.1001/jamanetworkopen.2021.28646.
• Analysis of Sociodemographic, Clinical, and Genomic Factors Associated With Breast Cancer Mortality in the Linked Surveillance, Epidemiology, and End Results and Medicare DatabaseRobinson TJ, Wilson LE, Marcom PK, Troester M, Lynch CF, Hernandez BY, Parrilla E, Brauer HA, Dinan MA. Analysis of Sociodemographic, Clinical, and Genomic Factors Associated With Breast Cancer Mortality in the Linked Surveillance, Epidemiology, and End Results and Medicare Database JAMA Network Open 2021, 4: e2131020. PMID: 34714340, PMCID: PMC8556625, DOI: 10.1001/jamanetworkopen.2021.31020.
• Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents.Spees L, Dinan M, Jackson B, Baggett C, Wilson L, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Wheeler S. Patient- and provider-level predictors of mortality among patients with metastatic renal cell carcinoma receiving oral anticancer agents. Journal Of Clinical Oncology 2021, 39: 116-116. DOI: 10.1200/jco.2020.39.28_suppl.116.
• Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma.Spees L, Wheeler S, Jackson B, Baggett C, Wilson L, Greiner M, Kaye D, Zhang T, George D, Scales C, Pritchard J, Leapman M, Gross C, Dinan M. Provider- and patient-level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma. Journal Of Clinical Oncology 2021, 39: 87-87. DOI: 10.1200/jco.2020.39.28_suppl.87.
• Provider‐ and patient‐level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinomaSpees LP, Wheeler SB, Jackson BE, Baggett CD, Wilson LE, Greiner MA, Kaye DR, Zhang T, George D, Scales CD, Pritchard JE, Leapman M, Gross CP, Dinan MA. Provider‐ and patient‐level predictors of oral anticancer agent initiation and adherence in patients with metastatic renal cell carcinoma Cancer Medicine 2021, 10: 6653-6665. PMID: 34480518, PMCID: PMC8495289, DOI: 10.1002/cam4.4201.
• PD46-08 MEDIATORS OF RACIAL DISPARITY IN THE USE OF PROSTATE MRILeapman M, Dinan M, Pasha S, Washington S, Ma X, Gross C. PD46-08 MEDIATORS OF RACIAL DISPARITY IN THE USE OF PROSTATE MRI Investigative Urology 2021, 206 DOI: 10.1097/ju.0000000000002060.08.
• Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United StatesWilson LE, Spees L, Pritchard J, Greiner MA, Scales CD, Baggett CD, Kaye D, George DJ, Zhang T, Wheeler SB, Dinan MA. Real-World Utilization of Oral Anticancer Agents and Related Costs in Older Adults with Metastatic Renal Cell Carcinoma in the United States Kidney Cancer 2021, 5: 115-127. PMID: 34632169, PMCID: PMC8474520, DOI: 10.3233/kca-210119.
• Challenges in Predicting Future Costs for Metastatic Breast CancerDinan MA, Greenup RA. Challenges in Predicting Future Costs for Metastatic Breast Cancer JNCI Cancer Spectrum 2021, 5: pkab064. PMID: 34409256, PMCID: PMC8364672, DOI: 10.1093/jncics/pkab064.
• Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma.Wheeler SB, Spees LP, Jackson BE, Baggett CD, Wilson LE, Greiner MA, Kaye DR, Zhang T, George D, Scales CD, Pritchard JE, Dinan MA. Patterns and Predictors of Oral Anticancer Agent Use in Diverse Patients With Metastatic Renal Cell Carcinoma. JCO Oncology Practice 2021, 17: e1895-e1904. PMID: 34138665, PMCID: PMC8678030, DOI: 10.1200/op.20.01082.
• Mediators of racial disparity in the use of prostate MRI.Leapman M, Dinan M, Pasha S, Washington S, Ma X, Gross C. Mediators of racial disparity in the use of prostate MRI. Journal Of Clinical Oncology 2021, 39: 6554-6554. DOI: 10.1200/jco.2021.39.15_suppl.6554.
• Predictors of Chronic Opioid Use: A Population-level Analysis of North Carolina Cancer Survivors Using Multi-Payer ClaimsCheck DK, Bagett C, Kim K, Roberts AW, Roberts MC, Robinson T, Oeffinger KC, Dinan MA. Predictors of Chronic Opioid Use: A Population-level Analysis of North Carolina Cancer Survivors Using Multi-Payer Claims Journal Of The National Cancer Institute 2021, 113: djab082-. PMID: 33881543, PMCID: PMC8562975, DOI: 10.1093/jnci/djab082.
• Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer TherapeuticsVarma T, Wallach JD, Miller JE, Schnabel D, Skydel JJ, Zhang AD, Dinan MA, Ross JS, Gross CP. Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics JAMA Network Open 2021, 4: e217063. PMID: 33877309, PMCID: PMC8058642, DOI: 10.1001/jamanetworkopen.2021.7063.
• Patterns and predictors of oral anticancer agent utilization in diverse metastatic renal cell carcinoma patients.Wheeler S, Spees L, Jackson B, Baggett C, Wilson L, Greiner M, George D, Scales C, Pritchard J, Dinan M. Patterns and predictors of oral anticancer agent utilization in diverse metastatic renal cell carcinoma patients. Journal Of Clinical Oncology 2021, 39: 279-279. DOI: 10.1200/jco.2021.39.6_suppl.279.
• Oral anticancer agent (OAA) adherence and survival in elderly patients with metastatic renal cell carcinoma (mRCC).Dinan M, Wilson L, Greiner M, Spees L, Pritchard J, Zhang T, Kaye D, George D, Scales C, Wheeler S. Oral anticancer agent (OAA) adherence and survival in elderly patients with metastatic renal cell carcinoma (mRCC). Journal Of Clinical Oncology 2021, 39: 280-280. DOI: 10.1200/jco.2021.39.6_suppl.280.
• Abstract SS1-11: Comprehensive analysis of health services, sociodemographic, clinical, and genomic factors driving locally advanced breast cancer mortality via a first-in-kind linkage of SEER-Medicare data with physical tumor samplesRobinson T, Wilson L, Marcom P, Troester M, Lynch C, Hernandez B, Castellar E, Brauer H, Enewold L, Dinan M. Abstract SS1-11: Comprehensive analysis of health services, sociodemographic, clinical, and genomic factors driving locally advanced breast cancer mortality via a first-in-kind linkage of SEER-Medicare data with physical tumor samples Cancer Research 2021, 81: ss1-11-ss1-11. DOI: 10.1158/1538-7445.sabcs20-ss1-11.
• Treatment at Integrated Centers Might Bridge the Academic-Community Survival Gap in Patients With Metastatic Non-Small Cell Carcinoma of the LungRamalingam S, Dinan M, Crawford J. Treatment at Integrated Centers Might Bridge the Academic-Community Survival Gap in Patients With Metastatic Non-Small Cell Carcinoma of the Lung Clinical Lung Cancer 2021, 22: e646-e653. PMID: 33582071, DOI: 10.1016/j.cllc.2020.12.013.
• Rapid rise in the cost of targeted cancer therapies for Medicare patients with solid tumors from 2006 to 2015Wilson LE, Greiner MA, Altomare I, Rotter J, Dinan MA. Rapid rise in the cost of targeted cancer therapies for Medicare patients with solid tumors from 2006 to 2015 Journal Of Geriatric Oncology 2020, 12: 375-380. PMID: 33250425, DOI: 10.1016/j.jgo.2020.11.007.
• Disparities in utilization of oral anticancer agents and related costs in elderly patients with metastatic renal cell carcinoma in the United States.Wilson L, Spees L, Pritchard J, Greiner M, Scales C, Baggett C, Kaye D, George D, Zhang T, Wheeler S, Dinan M. Disparities in utilization of oral anticancer agents and related costs in elderly patients with metastatic renal cell carcinoma in the United States. Journal Of Clinical Oncology 2020, 38: 106-106. DOI: 10.1200/jco.2020.38.29_suppl.106.
• Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma diagnosed between 2008 and 2012Dinan MA, Georgieva MV, Li Y, Zhang T, Harrison M, Shenolikar R, Scales CD. Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma diagnosed between 2008 and 2012 Journal Of Geriatric Oncology 2020, 12: 298-304. PMID: 32912737, DOI: 10.1016/j.jgo.2020.08.005.
• Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial AdoptionDinan MA, Wilson LE, Reed SD, Griggs JJ, Norton EC. Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption Clinical Breast Cancer 2020, 20: 487-494.e1. PMID: 32653473, DOI: 10.1016/j.clbc.2020.05.010.
• Prevalence, screening, treatment, and complications of osteoporosis and osteopenia in Medicare patients with chronic lymphocytic leukemia (CLL).Brander D, Oeffinger K, Greiner M, Dinan M. Prevalence, screening, treatment, and complications of osteoporosis and osteopenia in Medicare patients with chronic lymphocytic leukemia (CLL). Journal Of Clinical Oncology 2020, 38: e24050-e24050. DOI: 10.1200/jco.2020.38.15_suppl.e24050.
• Proposal for Value-Based, Tiered Reimbursement for Tumor Biomarker Tests to Promote Innovation and Evidence Generation.Dinan MA, Lyman GH, Schilsky RL, Hayes DF. Proposal for Value-Based, Tiered Reimbursement for Tumor Biomarker Tests to Promote Innovation and Evidence Generation. JCO Precision Oncology 2019, 3: 1-10. PMID: 35100733, DOI: 10.1200/po.19.00210.
• Simulated Costs of the ASCO Patient-Centered Oncology Payment Model in Medicare Beneficiaries With Newly Diagnosed Advanced Ovarian Cancer.Moss HA, Havrilesky LJ, Wang FF, Georgieva MV, Hendrix LH, Dinan MA. Simulated Costs of the ASCO Patient-Centered Oncology Payment Model in Medicare Beneficiaries With Newly Diagnosed Advanced Ovarian Cancer. JCO Oncology Practice 2019, 15: e1018-e1027. PMID: 31613721, DOI: 10.1200/jop.19.00026.
• OA11.03 Survival Disparities Between Academic and Community Centers in Advanced Lung Cancer in the US: Can We Bridge the Gap?Ramalingam S, Dinan M, Crawford J. OA11.03 Survival Disparities Between Academic and Community Centers in Advanced Lung Cancer in the US: Can We Bridge the Gap? Journal Of Thoracic Oncology 2019, 14: s234-s235. DOI: 10.1016/j.jtho.2019.08.467.
• Low Risk Thyroid Cancer in Older Adults: More Extensive Surgery Comes with Increased Cost of SurveillanceZambeli-Ljepovic A, Wang F, Dinan M, Hyslop T, Stang M, Roman S, Sosa J, Scheri R. Low Risk Thyroid Cancer in Older Adults: More Extensive Surgery Comes with Increased Cost of Surveillance Journal Of The American College Of Surgeons 2019, 229: s78. DOI: 10.1016/j.jamcollsurg.2019.08.184.
• Extent of surgery for low-risk thyroid cancer in the elderly: Equipoise in survival but not in short-term outcomesZambeli-Ljepović A, Wang F, Dinan MA, Hyslop T, Stang MT, Roman SA, Sosa JA, Scheri RP. Extent of surgery for low-risk thyroid cancer in the elderly: Equipoise in survival but not in short-term outcomes Surgery 2019, 166: 895-900. PMID: 31288935, PMCID: PMC6802283, DOI: 10.1016/j.surg.2019.05.035.
• Low-Risk Thyroid Cancer in Elderly: Total Thyroidectomy/RAI Predominates but Lacks Survival AdvantageZambeli-Ljepović A, Wang F, Dinan MA, Hyslop T, Roman SA, Sosa J, Scheri RP. Low-Risk Thyroid Cancer in Elderly: Total Thyroidectomy/RAI Predominates but Lacks Survival Advantage Journal Of Surgical Research 2019, 243: 189-197. PMID: 31185435, PMCID: PMC6773493, DOI: 10.1016/j.jss.2019.05.029.
• The Economic Impact of Genomic Testing in Breast CancerDinan M. The Economic Impact of Genomic Testing in Breast Cancer Oncology Times 2019, 41: 12,13,14,23-23. DOI: 10.1097/01.cot.0000559641.38121.c4.
• Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancerRotter J, Wilson L, Greiner MA, Pollack CE, Dinan M. Shared-patient physician networks and their impact on the uptake of genomic testing in breast cancer Breast Cancer Research And Treatment 2019, 176: 445-451. PMID: 31028607, PMCID: PMC6556129, DOI: 10.1007/s10549-019-05248-2.
• Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011.Dinan MA, Wilson LE, Reed SD. Chemotherapy Costs and 21-Gene Recurrence Score Genomic Testing Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005 to 2011. Journal Of The National Comprehensive Cancer Network 2019, 17: 245-254. PMID: 30865923, DOI: 10.6004/jnccn.2018.7097.
• Abstract P4-09-08: Shared-patient physician networks and their impact on the uptake of genomic testing in early-stage breast cancerRotter J, Wilson L, Greiner M, Pollack C, Dinan M. Abstract P4-09-08: Shared-patient physician networks and their impact on the uptake of genomic testing in early-stage breast cancer Cancer Research 2019, 79: p4-09-08-p4-09-08. DOI: 10.1158/1538-7445.sabcs18-p4-09-08.
• Initial Adoption of Recombinant Human Thyroid-Stimulating Hormone Following Thyroidectomy in the Medicare Thyroid Cancer Patient PopulationDinan MA, Li Y, Reed SD, Sosa JA. Initial Adoption of Recombinant Human Thyroid-Stimulating Hormone Following Thyroidectomy in the Medicare Thyroid Cancer Patient Population Endocrine Practice 2018, 25: 31-42. PMID: 30383499, DOI: 10.4158/ep-2018-0253.
• Nationwide utilization and costs of targeted anti-cancer drugs for elderly patients with solid tumors in the United States, 2004-2015.Wilson L, Greiner M, Altomare I, Rotter J, Dinan M. Nationwide utilization and costs of targeted anti-cancer drugs for elderly patients with solid tumors in the United States, 2004-2015. Journal Of Clinical Oncology 2018, 36: 23-23. DOI: 10.1200/jco.2018.36.30_suppl.23.
• Survival Comparison in Patients with Stage IV Lung Cancer in Academic versus Community Centers in the United StatesRamalingam S, Dinan MA, Crawford J. Survival Comparison in Patients with Stage IV Lung Cancer in Academic versus Community Centers in the United States Journal Of Thoracic Oncology 2018, 13: 1842-1850. PMID: 30312680, DOI: 10.1016/j.jtho.2018.09.007.
• Can the ASCO alternative payment model achieve cost savings in ovarian cancer care?Moss H, Dinan M, Georgieva M, Hendrix L, Havrilesky L. Can the ASCO alternative payment model achieve cost savings in ovarian cancer care? Gynecologic Oncology 2018, 149: 17-18. DOI: 10.1016/j.ygyno.2018.04.044.
• Advanced imaging and hospice use in end-of-life cancer careDinan MA, Curtis LH, Setoguchi S, Cheung WY. Advanced imaging and hospice use in end-of-life cancer care Supportive Care In Cancer 2018, 26: 3619-3625. PMID: 29728843, DOI: 10.1007/s00520-018-4223-0.
• PHS152 The Impact of Functional Status and Multi-Morbidity On Surveillance Use Among Medicare Beneficiaries with Bladder CancerGeorgieva M, Lund J, Nielsen M, Trogdon J, Dinan M, Weinberger M, Wheeler S. PHS152 The Impact of Functional Status and Multi-Morbidity On Surveillance Use Among Medicare Beneficiaries with Bladder Cancer Value In Health 2018, 21: s141. DOI: 10.1016/j.jval.2018.04.951.
• Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008–2011Wilson LE, Pollack CE, Greiner MA, Dinan MA. Association between physician characteristics and the use of 21-gene recurrence score genomic testing among Medicare beneficiaries with early-stage breast cancer, 2008–2011 Breast Cancer Research And Treatment 2018, 170: 361-371. PMID: 29536319, DOI: 10.1007/s10549-018-4746-6.
• Androgen deprivation therapy (ADT) and cardiovascular mortality (CVD) in men with early-stage prostate cancer (PC) receiving curative radiation therapy (RT).Hanlon A, Fleming S, Hamilton A, Dinan M, Melloni C, Harrison M, Khouri M, Wu X, Wilson J, Lipscomb J, Cress R, Anderson R, Kimmick G. Androgen deprivation therapy (ADT) and cardiovascular mortality (CVD) in men with early-stage prostate cancer (PC) receiving curative radiation therapy (RT). Journal Of Clinical Oncology 2018, 36: 127-127. DOI: 10.1200/jco.2018.36.7_suppl.127.
• The Economics of Oncology Clinical TrialsDinan M, Reed S. The Economics of Oncology Clinical Trials 2018 DOI: 10.1891/9780826168733.0041.
• Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma.Dinan M, Georgieva M, Shenolikar R, Scales C. Real-world systemic therapy utilization in Medicare patients with locally advanced or metastatic urothelial carcinoma. Journal Of Clinical Oncology 2018, 36: 415-415. DOI: 10.1200/jco.2018.36.6_suppl.415.
• Abstract P6-09-10: Provider characteristics and receipt of oncotype Dx testing in women diagnosed with early stage breast cancer using SEER-Medicare dataDinan M, Wilson L, Greiner M, Pollack C. Abstract P6-09-10: Provider characteristics and receipt of oncotype Dx testing in women diagnosed with early stage breast cancer using SEER-Medicare data Cancer Research 2018, 78: p6-09-10-p6-09-10. DOI: 10.1158/1538-7445.sabcs17-p6-09-10.
• 4B.02 Increasing Survival in Stage IV NSCLC in Academic versus Community Based Centers in the National Cancer Database Topic: Medical OncologyRamalingam S, Dinan M, Crawford J. 4B.02 Increasing Survival in Stage IV NSCLC in Academic versus Community Based Centers in the National Cancer Database Topic: Medical Oncology Journal Of Thoracic Oncology 2017, 12: s1560. DOI: 10.1016/j.jtho.2017.09.029.
• Trends in hospital-physician integration in medical oncology.Clough JD, Dinan MA, Schulman KA. Trends in hospital-physician integration in medical oncology. The American Journal Of Managed Care 2017, 23: 624-627. PMID: 29087634.
• Use of Whole Brain Radiation Therapy and Immune Checkpoint Inhibition in the Management of Brain MetastasesSavla B, Ahmed K, Yu M, Perez B, Dinan M, Mason N, Robinson T. Use of Whole Brain Radiation Therapy and Immune Checkpoint Inhibition in the Management of Brain Metastases International Journal Of Radiation Oncology • Biology • Physics 2017, 99: e105. DOI: 10.1016/j.ijrobp.2017.06.842.
• Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent datasetHarowicz MR, Robinson TJ, Dinan MA, Saha A, Marks JR, Marcom PK, Mazurowski MA. Algorithms for prediction of the Oncotype DX recurrence score using clinicopathologic data: a review and comparison using an independent dataset Breast Cancer Research And Treatment 2017, 162: 1-10. PMID: 28064383, PMCID: PMC5909985, DOI: 10.1007/s10549-016-4093-4.
• ONCOLOGISTS’ BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDYRoberts MC, Bryson A, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes K, Wheeler SB. ONCOLOGISTS’ BARRIERS AND FACILITATORS FOR ONCOTYPE DX USE: QUALITATIVE STUDY International Journal Of Technology Assessment In Health Care 2016, 32: 355-361. PMID: 27958190, PMCID: PMC6526532, DOI: 10.1017/s026646231600060x.
• PS01.61: Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now (REVOLUTION): Registry Study in Progress Topic: Medical OncologyKim E, Dinan M, Islam K, Fernandes A, Schwartzberg L, Croft E, Brahmer J, Mansfield A, Hyslop T, Burke L, Crawford J. PS01.61: Registry for the EVolution Of LUng Cancer Therapy Implementation and Outcomes Now (REVOLUTION): Registry Study in Progress Topic: Medical Oncology Journal Of Thoracic Oncology 2016, 11: s308-s309. DOI: 10.1016/j.jtho.2016.09.096.
• Health Services ResearchDinan M, Hirsch B, Abernethy A. Health Services Research 2016, 1-11. DOI: 10.1002/9781119000822.hfcm051.
• How Many Lymph Nodes Are Enough? Assessing the Adequacy of Lymph Node Yield for Papillary Thyroid CancerRobinson TJ, Thomas S, Dinan MA, Roman S, Sosa JA, Hyslop T. How Many Lymph Nodes Are Enough? Assessing the Adequacy of Lymph Node Yield for Papillary Thyroid Cancer Journal Of Clinical Oncology 2016, 34: 3434-3439. PMID: 27528716, PMCID: PMC6366339, DOI: 10.1200/jco.2016.67.6437.
• Patient-Centered Communication for Discussing Oncotype DX TestingRoberts MC, Bryson A, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes KE, Wheeler SB. Patient-Centered Communication for Discussing Oncotype DX Testing Cancer Investigation 2016, 34: 205-212. PMID: 27124287, PMCID: PMC4984670, DOI: 10.3109/07357907.2016.1172637.
• Chemotherapy costs associated with receipt of the adoption of oncotype DX in early-stage breast cancer within the SEER-Medicare population.Dinan M, Mi X, Reed S, Lyman G, Curtis L. Chemotherapy costs associated with receipt of the adoption of oncotype DX in early-stage breast cancer within the SEER-Medicare population. Journal Of Clinical Oncology 2016, 34: 32-32. DOI: 10.1200/jco.2016.34.7_suppl.32.
• Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancerRuel E, Thomas S, Dinan MA, Perkins JM, Roman SA, Sosa JA. Knowledge of pathologically versus clinically negative lymph nodes is associated with reduced use of radioactive iodine post-thyroidectomy for low-risk papillary thyroid cancer Endocrine 2015, 52: 579-586. PMID: 26708045, PMCID: PMC4880494, DOI: 10.1007/s12020-015-0826-0.
• Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast CancerRoberts MC, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes KE, Carey LA, Troester MA, Wheeler SB. Racial Variation in the Uptake of Oncotype DX Testing for Early-Stage Breast Cancer Journal Of Clinical Oncology 2015, 34: 130-138. PMID: 26598755, PMCID: PMC4872005, DOI: 10.1200/jco.2015.63.2489.
• Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009Dinan MA, Mi X, Reed SD, Lyman GH, Curtis LH. Association Between Use of the 21-Gene Recurrence Score Assay and Receipt of Chemotherapy Among Medicare Beneficiaries With Early-Stage Breast Cancer, 2005-2009 JAMA Oncology 2015, 1: 1098. PMID: 26313372, DOI: 10.1001/jamaoncol.2015.2722.
• Nationwide Utilization of Cardiac Imaging in Patients Undergoing External Beam Radiation Therapy With and Without Cardiotoxic ChemotherapyDinan M, Li Y, Reed S, Cheung W. Nationwide Utilization of Cardiac Imaging in Patients Undergoing External Beam Radiation Therapy With and Without Cardiotoxic Chemotherapy International Journal Of Radiation Oncology • Biology • Physics 2015, 93: e368-e369. DOI: 10.1016/j.ijrobp.2015.07.1487.
• Abstract B53: Racial variation in the uptake of a 21-tumor gene assay in the Carolina Breast Cancer Study cohortRoberts M, Wheeler S, Reeder-Hayes K, Dusetzina S, Dinan M, Weinberger M. Abstract B53: Racial variation in the uptake of a 21-tumor gene assay in the Carolina Breast Cancer Study cohort Cancer Epidemiology Biomarkers & Prevention 2015, 24: b53-b53. DOI: 10.1158/1538-7755.disp14-b53.
• Otolaryngology utilization of speech‐language pathology services for voice disordersCohen SM, Dinan MA, Kim J, Roy N. Otolaryngology utilization of speech‐language pathology services for voice disorders The Laryngoscope 2015, 126: 906-912. PMID: 26308555, DOI: 10.1002/lary.25574.
• Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate CancerDinan MA, Li Y, Zhang Y, Stewart SB, Curtis LH, George DJ, Reed SD. Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer Clinical Genitourinary Cancer 2015, 14: 28-37.e2. PMID: 26382223, PMCID: PMC4698191, DOI: 10.1016/j.clgc.2015.07.006.
• Longitudinal Trends in Costs of Palliative Radiation for Metastatic Prostate CancerRobinson TJ, Dinan MA, Li Y, Lee WR, Reed SD. Longitudinal Trends in Costs of Palliative Radiation for Metastatic Prostate Cancer Journal Of Palliative Medicine 2015, 18: 933-939. PMID: 26241733, PMCID: PMC4638209, DOI: 10.1089/jpm.2015.0171.
• Minimally Invasive Versus Open Pancreaticoduodenectomy for CancerAdam MA, Choudhury K, Dinan MA, Reed SD, Scheri RP, Blazer DG, Roman SA, Sosa JA. Minimally Invasive Versus Open Pancreaticoduodenectomy for Cancer Annals Of Surgery 2015, 262: 372-377. PMID: 26158612, DOI: 10.1097/sla.0000000000001055.
• Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testingRoberts MC, Weinberger M, Dusetzina SB, Dinan MA, Reeder-Hayes KE, Troester MA, Carey LA, Wheeler SB. Racial variation in adjuvant chemotherapy initiation among breast cancer patients receiving oncotype DX testing Breast Cancer Research And Treatment 2015, 153: 191-200. PMID: 26216535, PMCID: PMC4562432, DOI: 10.1007/s10549-015-3518-9.
• Presence and Number of Lymph Node Metastases Are Associated With Compromised Survival for Patients Younger Than Age 45 Years With Papillary Thyroid CancerAdam MA, Pura J, Goffredo P, Dinan MA, Reed SD, Scheri RP, Hyslop T, Roman SA, Sosa JA. Presence and Number of Lymph Node Metastases Are Associated With Compromised Survival for Patients Younger Than Age 45 Years With Papillary Thyroid Cancer Journal Of Clinical Oncology 2015, 33: 2370-2375. PMID: 26077238, DOI: 10.1200/jco.2014.59.8391.
• Nationwide utilization of cardiac imaging in patients undergoing cardiotoxic chemotherapy.Dinan M, Li Y, Reed S, Cheung W. Nationwide utilization of cardiac imaging in patients undergoing cardiotoxic chemotherapy. Journal Of Clinical Oncology 2015, 33: 6592-6592. DOI: 10.1200/jco.2015.33.15_suppl.6592.
• Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009Dinan MA, Mi X, Reed SD, Hirsch BR, Lyman GH, Curtis LH. Initial Trends in the Use of the 21-Gene Recurrence Score Assay for Patients With Breast Cancer in the Medicare Population, 2005-2009 JAMA Oncology 2015, 1: 158-166. PMID: 26181015, DOI: 10.1001/jamaoncol.2015.43.
• Patterns of Use and Cost for Inappropriate Radioactive Iodine Treatment for Thyroid Cancer in the United States: Use and MisuseGoffredo P, Thomas SM, Dinan MA, Perkins JM, Roman SA, Sosa JA. Patterns of Use and Cost for Inappropriate Radioactive Iodine Treatment for Thyroid Cancer in the United States: Use and Misuse JAMA Internal Medicine 2015, 175: 638-640. PMID: 25686394, DOI: 10.1001/jamainternmed.2014.8020.
• Costs, Effectiveness, and Workload Impact of Management Strategies for Women With an Adnexal MassHavrilesky L, Dinan M, Sfakianos G, Curtis L, Barnett J, Van Gorp T, Myers E. Costs, Effectiveness, and Workload Impact of Management Strategies for Women With an Adnexal Mass Obstetrical & Gynecological Survey 2015, 70: 253-255. DOI: 10.1097/01.ogx.0000464937.42384.2d.
• Adjuvant Radioactive Iodine Therapy Is Associated With Improved Survival for Patients With Intermediate-Risk Papillary Thyroid CancerRuel E, Thomas S, Dinan M, Perkins JM, Roman SA, Sosa JA. Adjuvant Radioactive Iodine Therapy Is Associated With Improved Survival for Patients With Intermediate-Risk Papillary Thyroid Cancer The Journal Of Clinical Endocrinology & Metabolism 2015, 100: 1529-1536. PMID: 25642591, PMCID: PMC4399282, DOI: 10.1210/jc.2014-4332.
• Management of chemotherapy-induced neutropenia: measuring quality, cost, and value.Dinan MA, Hirsch BR, Lyman GH. Management of chemotherapy-induced neutropenia: measuring quality, cost, and value. Journal Of The National Comprehensive Cancer Network 2015, 13: e1-7. PMID: 25583775, DOI: 10.6004/jnccn.2015.0014.
• Impact of extent of surgery on survival for papillary thyroid cancer patients younger than 45 years.Abdelgadir Adam M, Pura J, Goffredo P, Dinan MA, Hyslop T, Reed SD, Scheri RP, Roman SA, Sosa JA. Impact of extent of surgery on survival for papillary thyroid cancer patients younger than 45 years. The Journal Of Clinical Endocrinology & Metabolism 2015, 100: 115-21. PMID: 25337927, PMCID: PMC5399499, DOI: 10.1210/jc.2014-3039.
• Costs, Effectiveness, and Workload Impact of Management Strategies for Women With an Adnexal MassHavrilesky LJ, Dinan M, Sfakianos GP, Curtis LH, Barnett JC, Van Gorp T, Myers ER. Costs, Effectiveness, and Workload Impact of Management Strategies for Women With an Adnexal Mass Journal Of The National Cancer Institute 2014, 107: 322. PMID: 25515232, DOI: 10.1093/jnci/dju322.
• Exploring variation in care: alternative conceptual models.Dinan MA, Schulman KA. Exploring variation in care: alternative conceptual models. Annals Of Internal Medicine 2014, 161: 835-6. PMID: 25437412, DOI: 10.7326/m14-2382.
• Association between Oncotype DX and receipt of chemotherapy in early-stage breast cancer within the Medicare population from 2004 to 2007.Dinan M, Mi X, Reed S, Lyman G, Curtis L. Association between Oncotype DX and receipt of chemotherapy in early-stage breast cancer within the Medicare population from 2004 to 2007. Journal Of Clinical Oncology 2014, 32: 309-309. DOI: 10.1200/jco.2014.32.30_suppl.309.
• Extent of Surgery for Papillary Thyroid Cancer Is Not Associated With SurvivalAdam MA, Pura J, Gu L, Dinan MA, Tyler DS, Reed SD, Scheri R, Roman SA, Sosa JA. Extent of Surgery for Papillary Thyroid Cancer Is Not Associated With Survival Annals Of Surgery 2014, 260: 601-607. PMID: 25203876, PMCID: PMC4532384, DOI: 10.1097/sla.0000000000000925.
• Intensity Modulated Radiation Therapy Utilization in the Treatment of Gastrointestinal Malignancies Between 2000 and 2009 in the SEER-Medicare PopulationPalta M, Czito B, Willett C, Dinan M. Intensity Modulated Radiation Therapy Utilization in the Treatment of Gastrointestinal Malignancies Between 2000 and 2009 in the SEER-Medicare Population International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s401-s402. DOI: 10.1016/j.ijrobp.2014.05.1281.
• Association Between Diagnostic CT Utilization and Radiation Therapy at the End of Life (EOL) in Elderly Breast and Prostate Cancer Patients: 2002-2007Dinan M, Curtis L, Setoguchi-Iwata S, Cheung W. Association Between Diagnostic CT Utilization and Radiation Therapy at the End of Life (EOL) in Elderly Breast and Prostate Cancer Patients: 2002-2007 International Journal Of Radiation Oncology • Biology • Physics 2014, 90: s582. DOI: 10.1016/j.ijrobp.2014.05.1751.
• Treatment Patterns and Outcomes for Patients with Adrenocortical Carcinoma Associated with Hospital Case Volume in the United StatesGratian L, Pura J, Dinan M, Reed S, Scheri R, Roman S, Sosa JA. Treatment Patterns and Outcomes for Patients with Adrenocortical Carcinoma Associated with Hospital Case Volume in the United States Annals Of Surgical Oncology 2014, 21: 3509-3514. PMID: 25069860, PMCID: PMC4515350, DOI: 10.1245/s10434-014-3931-z.
• Robotic Thyroidectomy for Cancer in the US: Patterns of Use and Short-Term OutcomesAbdelgadir Adam M, Speicher P, Pura J, Dinan MA, Reed SD, Roman SA, Sosa JA. Robotic Thyroidectomy for Cancer in the US: Patterns of Use and Short-Term Outcomes Annals Of Surgical Oncology 2014, 21: 3859-3864. PMID: 24934584, PMCID: PMC4519825, DOI: 10.1245/s10434-014-3838-8.
• Impact of Extent of Surgery on Survival in Patients with Small Nonfunctional Pancreatic Neuroendocrine Tumors in the United StatesGratian L, Pura J, Dinan M, Roman S, Reed S, Sosa JA. Impact of Extent of Surgery on Survival in Patients with Small Nonfunctional Pancreatic Neuroendocrine Tumors in the United States Annals Of Surgical Oncology 2014, 21: 3515-3521. PMID: 24841347, PMCID: PMC4510956, DOI: 10.1245/s10434-014-3769-4.
• Initial utilization of Oncotype DX in the Medicare population between 2005 and 2007.Dinan M, Mi X, Reed S, Hirsch B, Lyman G, Curtis L. Initial utilization of Oncotype DX in the Medicare population between 2005 and 2007. Journal Of Clinical Oncology 2014, 32: 6508-6508. DOI: 10.1200/jco.2014.32.15_suppl.6508.
• Association between CT utilization and radiation therapy at the end of life (EOL) in elderly breast and prostate cancer patients.Dinan M, Curtis L, Setoguchi S, Cheung W. Association between CT utilization and radiation therapy at the end of life (EOL) in elderly breast and prostate cancer patients. Journal Of Clinical Oncology 2014, 32: 6529-6529. DOI: 10.1200/jco.2014.32.15_suppl.6529.
• Redistribution of Health Care Costs after the Adoption of Positron Emission Tomography among Medicare Beneficiaries with Non–Small-Cell Lung Cancer, 1998–2005Dinan MA, Curtis LH, Carpenter WR, Biddle AK, Abernethy AP, Patz EF, Schulman KA, Weinberger M. Redistribution of Health Care Costs after the Adoption of Positron Emission Tomography among Medicare Beneficiaries with Non–Small-Cell Lung Cancer, 1998–2005 Journal Of Thoracic Oncology 2014, 9: 512-518. PMID: 24736074, DOI: 10.1097/jto.0000000000000102.
• Diagnosis Change in Voice‐Disordered Patients Evaluated by Primary Care and/or Otolaryngology: A Longitudinal StudyCohen SM, Dinan MA, Roy N, Kim J, Courey M. Diagnosis Change in Voice‐Disordered Patients Evaluated by Primary Care and/or Otolaryngology: A Longitudinal Study Otolaryngology 2013, 150: 95-102. PMID: 24264568, DOI: 10.1177/0194599813512982.
• Oral Contraceptive Use and Risk of Breast, Cervical, Colorectal, and Endometrial Cancers: A Systematic ReviewGierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER. Oral Contraceptive Use and Risk of Breast, Cervical, Colorectal, and Endometrial Cancers: A Systematic Review Cancer Epidemiology Biomarkers & Prevention 2013, 22: 1931-1943. PMID: 24014598, DOI: 10.1158/1055-9965.epi-13-0298.
• Oral Contraceptives and Risk of Ovarian Cancer and Breast Cancer Among High-Risk Women: A Systematic Review and Meta-AnalysisMoorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Urrutia R, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER. Oral Contraceptives and Risk of Ovarian Cancer and Breast Cancer Among High-Risk Women: A Systematic Review and Meta-Analysis Journal Of Clinical Oncology 2013, 31: 4188-4198. PMID: 24145348, DOI: 10.1200/jco.2013.48.9021.
• Longitudinal Trends in Costs for Palliative Radiation for Metastatic Prostate CancerRobinson T, Dinan M, Li Y, Lee W, Reed S. Longitudinal Trends in Costs for Palliative Radiation for Metastatic Prostate Cancer International Journal Of Radiation Oncology • Biology • Physics 2013, 87: s490. DOI: 10.1016/j.ijrobp.2013.06.1294.
• Changes in Radiation Therapy, Surgery, and Costs for Treatment of Non-Small Cell Lung Cancer After the Adoption of Positron Emission Tomography: 1998-2005Dinan M, Curtis L, Carpenter W, Biddle A, Abernethy A, Patz E, Schulman K, Weinberger M. Changes in Radiation Therapy, Surgery, and Costs for Treatment of Non-Small Cell Lung Cancer After the Adoption of Positron Emission Tomography: 1998-2005 International Journal Of Radiation Oncology • Biology • Physics 2013, 87: s41-s42. DOI: 10.1016/j.ijrobp.2013.06.110.
• Risk of Acute Thromboembolic Events With Oral Contraceptive UseUrrutia R, Coeytaux RR, McBroom AJ, Gierisch JM, Havrilesky LJ, Moorman PG, Lowery WJ, Dinan M, Hasselblad V, Sanders GD, Myers ER. Risk of Acute Thromboembolic Events With Oral Contraceptive Use Obstetrics And Gynecology 2013, 122: 380-389. PMID: 23969809, DOI: 10.1097/aog.0b013e3182994c43.
• Oral Contraceptive Pills as Primary Prevention for Ovarian CancerHavrilesky LJ, Moorman PG, Lowery WJ, Gierisch JM, Coeytaux RR, Urrutia RP, Dinan M, McBroom AJ, Hasselblad V, Sanders GD, Myers ER. Oral Contraceptive Pills as Primary Prevention for Ovarian Cancer Obstetrics And Gynecology 2013, 122: 139-147. PMID: 23743450, DOI: 10.1097/aog.0b013e318291c235.
• Oral contraceptive use for the primary prevention of ovarian cancer.Havrilesky LJ, Gierisch JM, Moorman PG, Coeytaux RR, Urrutia RP, Lowery WJ, Dinan M, McBroom AJ, Wing L, Musty MD, Lallinger KR, Hasselblad V, Sanders GD, Myers ER. Oral contraceptive use for the primary prevention of ovarian cancer. Evidence Report Technology Assessment 2013, 1-514. PMID: 24423062, PMCID: PMC4781074.
• Longitudinal trends in costs for palliative radiation for metastatic prostate cancer.Robinson T, Dinan M, Li Y, Lee R, Reed S. Longitudinal trends in costs for palliative radiation for metastatic prostate cancer. Journal Of Clinical Oncology 2013, 31: 6554-6554. DOI: 10.1200/jco.2013.31.15_suppl.6554.
• Association between high-cost imaging and hospice use at the end of life of cancer patients.Dinan M, Setoguchi S, Curtis L, Cheung W. Association between high-cost imaging and hospice use at the end of life of cancer patients. Journal Of Clinical Oncology 2013, 31: 6504-6504. DOI: 10.1200/jco.2013.31.15_suppl.6504.
• Resource use and costs in the last year of life among Medicare beneficiaries who died from prostate cancer versus with the disease between 2000 and 2007.Reed S, Dinan M, Li Y, Zhang Y, Curtis L, George D, Stewart S. Resource use and costs in the last year of life among Medicare beneficiaries who died from prostate cancer versus with the disease between 2000 and 2007. Journal Of Clinical Oncology 2013, 31: 6631-6631. DOI: 10.1200/jco.2013.31.15_suppl.6631.
• Reply to M.S. Hofman et alDinan MA, Carpenter WR, Patz EF, Abernethy AP, Biddle AK, Schulman KA, Curtis LH. Reply to M.S. Hofman et al Journal Of Clinical Oncology 2013, 31: 820-820. PMID: 23544205, DOI: 10.1200/jco.2012.46.7373.
• Variations in Use of PET among Medicare Beneficiaries with Non–Small Cell Lung Cancer, 1998–2007Dinan MA, Curtis LH, Carpenter WR, Biddle AK, Abernethy AP, Patz EF, Schulman KA, Weinberger M. Variations in Use of PET among Medicare Beneficiaries with Non–Small Cell Lung Cancer, 1998–2007 Radiology 2013, 267: 807-817. PMID: 23418003, DOI: 10.1148/radiol.12120174.
• Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancerReed SD, Dinan MA, Schulman KA, Lyman GH. Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer Genetics In Medicine 2012, 15: 203-211. PMID: 22975761, PMCID: PMC3743447, DOI: 10.1038/gim.2012.119.
• Stage Migration, Selection Bias, and Survival Associated With the Adoption of Positron Emission Tomography Among Medicare Beneficiaries With Non–Small-Cell Lung Cancer, 1998-2003Dinan MA, Curtis LH, Carpenter WR, Biddle AK, Abernethy AP, Patz EF, Schulman KA, Weinberger M. Stage Migration, Selection Bias, and Survival Associated With the Adoption of Positron Emission Tomography Among Medicare Beneficiaries With Non–Small-Cell Lung Cancer, 1998-2003 Journal Of Clinical Oncology 2012, 30: 2725-2730. PMID: 22753917, DOI: 10.1200/jco.2011.40.4392.
• P04.68. Costs associated with integrative medicine interventions on chronic painDinan M, Roberts R, Reed S, Wolever R, Abrams D, Dolor R. P04.68. Costs associated with integrative medicine interventions on chronic pain BMC Complementary Medicine And Therapies 2012, 12: p338. PMCID: PMC3373798, DOI: 10.1186/1472-6882-12-s1-p338.
• Cost-effectiveness of the 21-gene recurrence score assay in the setting of multifactorial decision making for chemotherapy in early-stage breast cancer.Reed S, Dinan M, Schulman K, Lyman G. Cost-effectiveness of the 21-gene recurrence score assay in the setting of multifactorial decision making for chemotherapy in early-stage breast cancer. Journal Of Clinical Oncology 2012, 30: 1525-1525. DOI: 10.1200/jco.2012.30.15_suppl.1525.
• Changes in Initial Treatment for Prostate Cancer Among Medicare Beneficiaries, 1999–2007Dinan MA, Robinson TJ, Zagar TM, Scales CD, Curtis LH, Reed SD, Lee WR, Schulman KA. Changes in Initial Treatment for Prostate Cancer Among Medicare Beneficiaries, 1999–2007 International Journal Of Radiation Oncology • Biology • Physics 2012, 82: e781-e786. PMID: 22331001, PMCID: PMC3418871, DOI: 10.1016/j.ijrobp.2011.11.024.
• Resource Use, Costs, and Utility Estimates for Patients with Cystic Fibrosis with Mild Impairment in Lung Function: Analysis of Data Collected Alongside a 48-Week Multicenter Clinical TrialDeWitt EM, Grussemeyer CA, Friedman JY, Dinan MA, Lin L, Schulman KA, Reed SD. Resource Use, Costs, and Utility Estimates for Patients with Cystic Fibrosis with Mild Impairment in Lung Function: Analysis of Data Collected Alongside a 48-Week Multicenter Clinical Trial Value In Health 2012, 15: 277-283. PMID: 22433759, DOI: 10.1016/j.jval.2011.11.027.
• Personalized medicine is more than genomic medicine: confusion over terminology impedes progress towards personalized healthcareSimmons LA, Dinan MA, Robinson TJ, Snyderman R. Personalized medicine is more than genomic medicine: confusion over terminology impedes progress towards personalized healthcare Personalized Medicine 2012, 9: 85-91. PMID: 29783292, DOI: 10.2217/pme.11.86.
• Financial implications of changes in the initial treatment of prostate cancer among Medicare beneficiaries.Dinan M, Robinson T, Zagar T, Scales C, Curtis L, Reed S, Schulman K, Lee W. Financial implications of changes in the initial treatment of prostate cancer among Medicare beneficiaries. Journal Of Clinical Oncology 2011, 29: 6115-6115. DOI: 10.1200/jco.2011.29.15_suppl.6115.
• Use of Patient-Reported Outcomes in Randomized, Double-Blind, Placebo-Controlled Clinical TrialsDinan MA, Compton KL, Dhillon JK, Hammill BG, DeWitt EM, Weinfurt KP, Schulman KA. Use of Patient-Reported Outcomes in Randomized, Double-Blind, Placebo-Controlled Clinical Trials Medical Care 2011, 49: 415-419. PMID: 21368680, PMCID: PMC3682647, DOI: 10.1097/mlr.0b013e3182064aa2.
• Commentary: Personalized Health Planning and the Patient Protection and Affordable Care Act: An Opportunity for Academic Medicine to Lead Health Care ReformDinan MA, Simmons LA, Snyderman R. Commentary: Personalized Health Planning and the Patient Protection and Affordable Care Act: An Opportunity for Academic Medicine to Lead Health Care Reform Academic Medicine 2010, 85: 1665-1668. PMID: 20844424, DOI: 10.1097/acm.0b013e3181f4ab3c.
• Changes in the Use and Costs of Diagnostic Imaging Among Medicare Beneficiaries With Cancer, 1999-2006Dinan MA, Curtis LH, Hammill BG, Patz EF, Abernethy AP, Shea AM, Schulman KA. Changes in the Use and Costs of Diagnostic Imaging Among Medicare Beneficiaries With Cancer, 1999-2006 JAMA 2010, 303: 1625-1631. PMID: 20424253, DOI: 10.1001/jama.2010.460.
• SplicerAV: a tool for mining microarray expression data for changes in RNA processingRobinson TJ, Dinan MA, Dewhirst M, Garcia-Blanco MA, Pearson JL. SplicerAV: a tool for mining microarray expression data for changes in RNA processing BMC Bioinformatics 2010, 11: 108. PMID: 20184770, PMCID: PMC2838864, DOI: 10.1186/1471-2105-11-108.
• Improving Health by Taking It PersonallySnyderman R, Dinan MA. Improving Health by Taking It Personally JAMA 2010, 303: 363-364. PMID: 20103762, DOI: 10.1001/jama.2010.34.
• Costs and length of stay for patients with and without sickle cell disease after hysterectomy, appendectomy, or knee replacementKamble S, Telen MJ, Dinan MA, Grussemeyer CA, Reed SD. Costs and length of stay for patients with and without sickle cell disease after hysterectomy, appendectomy, or knee replacement American Journal Of Hematology 2009, 85: 79-81. PMID: 20029954, PMCID: PMC2887617, DOI: 10.1002/ajh.21576.
• Outcomes of inpatients with and without sickle cell disease after high‐volume surgical proceduresDinan MA, Chou C, Hammill BG, Graham FL, Schulman KA, Telen MJ, Reed SD. Outcomes of inpatients with and without sickle cell disease after high‐volume surgical procedures American Journal Of Hematology 2009, 84: 703-709. PMID: 19787790, PMCID: PMC2783350, DOI: 10.1002/ajh.21520.
• CO4 COMPARISON OF INPATIENT COST ESTIMATION METHODS: USING DATA FROM A CYSTIC FIBROSIS TRIALDinan M, Dewitt E, Grussemeyer C, Reed S. CO4 COMPARISON OF INPATIENT COST ESTIMATION METHODS: USING DATA FROM A CYSTIC FIBROSIS TRIAL Value In Health 2009, 12: a7. DOI: 10.1016/s1098-3015(10)73094-1.
• Effects of Disclosing Financial Interests on Attitudes Toward Clinical ResearchWeinfurt KP, Hall MA, Dinan MA, DePuy V, Friedman JY, Allsbrook JS, Sugarman J. Effects of Disclosing Financial Interests on Attitudes Toward Clinical Research Journal Of General Internal Medicine 2008, 23: 860-866. PMID: 18386101, PMCID: PMC2517900, DOI: 10.1007/s11606-008-0590-4.
• Perspectives of clinical research coordinators on disclosing financial conflicts of interest to potential research participantsFriedman JY, Sugarman J, Dhillon JK, DePuy V, Pierre CK, Dinan MA, Allsbrook JS, Schulman KA, Weinfurt KP. Perspectives of clinical research coordinators on disclosing financial conflicts of interest to potential research participants Clinical Trials 2007, 4: 272-278. PMID: 17715256, DOI: 10.1177/1740774507079239.
• Developing model language for disclosing financial interests to potential clinical research participants.Weinfurt KP, Allsbrook JS, Friedman JY, Dinan MA, Hall MA, Schulman KA, Sugarman J. Developing model language for disclosing financial interests to potential clinical research participants. Ethics & Human Research 2007, 29: 1-5. PMID: 17364012, PMCID: PMC1825040.
• Comparison of Conflict of Interest Policies and Reported Practices in Academic Medical Centers in the United StatesDINAN MA, WEINFURT KP, FRIEDMAN JY, ALLSBROOK JS, GOTTLIEB J, SCHULMAN KA, HALL MA, DHILLON JK, SUGARMAN J. Comparison of Conflict of Interest Policies and Reported Practices in Academic Medical Centers in the United States Accountability In Research 2006, 13: 325-342. PMID: 17849643, PMCID: PMC2474571, DOI: 10.1080/08989620601003414.
• Views of potential research participants on financial conflicts of interest barriers and opportunities for effective disclosureWeinfurt K, Friedman J, Allsbrook J, Dinan M, Hall M, Sugarman J. Views of potential research participants on financial conflicts of interest barriers and opportunities for effective disclosure Journal Of General Internal Medicine 2006, 21: 901-906. DOI: 10.1007/bf02743135.
• Views of Potential Research Participants on Financial Conflicts of Interest: Barriers and Opportunities for Effective DisclosureWeinfurt KP, Friedman JY, Allsbrook JS, Dinan MA, Hall MA, Sugarman J. Views of Potential Research Participants on Financial Conflicts of Interest: Barriers and Opportunities for Effective Disclosure Journal Of General Internal Medicine 2006, 21: 901-906. PMID: 16918732, PMCID: PMC1831594, DOI: 10.1111/j.1525-1497.2006.00502.x.
• Policies of Academic Medical Centers for Disclosing Financial Conflicts of Interest to Potential Research ParticipantsWeinfurt KP, Dinan MA, Allsbrook JS, Friedman JY, Hall MA, Schulman KA, Sugarman J. Policies of Academic Medical Centers for Disclosing Financial Conflicts of Interest to Potential Research Participants Academic Medicine 2006, 81: 113-118. PMID: 16436571, PMCID: PMC1820630, DOI: 10.1097/00001888-200602000-00003.
• Disclosing Conflicts of Interest in Clinical Research: Views of Institutional Review Boards, Conflict of Interest Committees, and InvestigatorsWeinfurt KP, Friedman JY, Dinan MA, Allsbrook JS, Hall MA, Dhillon JK, Sugarman J. Disclosing Conflicts of Interest in Clinical Research: Views of Institutional Review Boards, Conflict of Interest Committees, and Investigators The Journal Of Law, Medicine & Ethics 2006, 34: 581-591. PMID: 17144182, PMCID: PMC1850937, DOI: 10.1111/j.1748-720x.2006.00072.x.